Article Corrected
Scott LJ, Yang LPH, Lyseng-Williamson KA. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. Drugs Aging 2012; 29 (3): 243–8
Correction Made
Page 244, table I, ‘Clinical benefits’ subsection: The third sentence, which previously read:
“Only second-line therapy available that prolongs overall survival” has now been corrected as follows:
“Only second-line hormonal therapy currently shown to prolong overall survival”
Note
All online versions of this article have been updated to reflect this correction.
Additional information
The original online version for this chapter can be found at http://dx.doi.org/10.2165/11209160-000000000-00000
Rights and permissions
About this article
Cite this article
Scott, L.J., Yang, L.P.H. & Lyseng-Williamson, K.A. Erratum to: Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. Drugs Aging 29, 1 (2012). https://doi.org/10.2165/11632600-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11632600-000000000-00000